What are the treatment options for vertigo?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment Options for Vertigo

The primary evidence-based treatments for vertigo depend on the underlying cause, with canalith repositioning procedures (Epley or Semont maneuver) being the first-line treatment for benign paroxysmal positional vertigo (BPPV), while medications like meclizine (25-100 mg daily) are indicated for vertigo associated with vestibular system diseases. 1, 2

Diagnostic Classification to Guide Treatment

Before initiating treatment, it's essential to classify vertigo based on its cause:

  1. Peripheral Causes (most common in primary care):

    • Benign Paroxysmal Positional Vertigo (BPPV) - 42% of cases
    • Vestibular Neuritis - 41% of cases
    • Ménière's Disease - 10% of cases
  2. Central Causes:

    • Vestibular Migraine - up to 14% of cases
    • Vascular causes - 3% of cases

Treatment Approaches by Specific Condition

1. Benign Paroxysmal Positional Vertigo (BPPV)

  • First-line treatment: Canalith repositioning procedures (CRPs)
    • Epley or Semont maneuver (80-90% success rate after 1-2 treatments) 1
    • These procedures should be performed before considering medication
  • Adjunct therapy: Vestibular rehabilitation exercises (particularly beneficial for elderly patients)
  • Important: The American Academy of Otolaryngology-Head and Neck Surgery recommends against routinely using vestibular suppressant medications for BPPV 1

2. Vestibular Neuritis/Labyrinthitis

  • Acute phase treatment:
    • Short course of oral corticosteroids (prednisone or methylprednisolone) for 7-14 days with tapering dose 1
    • Vestibular suppressants for symptom control only during acute phase
  • Recovery phase: Vestibular rehabilitation exercises to promote compensation

3. Ménière's Disease

  • First-line therapy: Low-salt diet combined with diuretics (reduces vertigo attacks by 56% compared to placebo) 1
  • For acute attacks: Vestibular suppressants and antiemetics
  • Refractory cases: Transtympanic gentamicin for patients with non-usable hearing 1

4. Vestibular Migraine

  • Prophylactic treatment: Beta-blockers, anticonvulsants, or antidepressants 1
  • Acute attacks: Similar management to other migraines

Pharmacological Options

1. Vestibular Suppressants

  • Meclizine (FDA-approved for vertigo):
    • Dosage: 25-100 mg daily in divided doses 2
    • Indicated specifically for vertigo associated with vestibular system diseases
    • Warning: May cause drowsiness; use caution when driving or operating machinery 2
    • Contraindicated in patients with hypersensitivity to meclizine 2

2. Other Medication Options

  • Antiemetics:

    • Prokinetic antiemetics (domperidone, metoclopramide) - useful for managing nausea without significantly interfering with vestibular compensation 1
    • Dopamine receptor antagonists (prochlorperazine, metoclopramide) 1
    • 5-HT3 antagonists (ondansetron) for severe nausea 1
  • Benzodiazepines (e.g., lorazepam):

    • For acute symptom control
    • Caution: Long-term use can delay vestibular compensation 1

Important Clinical Considerations

  • Avoid prolonged use of vestibular suppressants as they can delay central compensation and recovery 1
  • Reassess patients within 1 month after initial treatment to confirm symptom resolution 1
  • Avoid unnecessary imaging unless diagnosis is uncertain or additional symptoms warrant testing 1
  • Patient education is crucial:
    • Explain mechanism of vertigo
    • Discuss fall prevention strategies
    • Review warning signs requiring further evaluation
    • Provide reassurance about generally favorable prognosis
    • Explain possibility of recurrence (10-18% at 1 year, up to 36% long-term for BPPV) 1

Special Considerations

  • Elderly patients are at higher risk for falls; home safety assessment is crucial 1
  • Patients with asthma, glaucoma, or prostate enlargement should use meclizine with caution due to potential anticholinergic effects 2
  • Drug interactions: Meclizine may increase CNS depression when used with other CNS depressants, including alcohol 2

Remember that most vertigo cases in primary care are benign peripheral causes that can be effectively managed with appropriate treatment, and many will resolve with time and proper management.

References

Guideline

Diagnostic Evaluation and Management of Vertigo

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.